HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low – Time to Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) shares reached a new 52-week low during trading on Tuesday . The company traded as low as $11.70 and last traded at $11.70, with a volume of 13606 shares changing hands. The stock had previously closed at $11.99.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wall Street Zen downgraded HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Bank of America dropped their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Finally, Weiss Ratings downgraded HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $16.88.

HUTCHMED Trading Down 2.0%

The business has a 50 day moving average of $13.97 and a 200-day moving average of $14.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings results on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $290.50 million. On average, research analysts expect that HUTCHMED will post 0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its stake in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares during the last quarter. Bank of America Corp DE grew its stake in HUTCHMED by 5.9% during the 3rd quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after buying an additional 1,209 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in HUTCHMED by 3.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after buying an additional 1,680 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in HUTCHMED by 12.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after buying an additional 1,873 shares during the last quarter. Finally, State Street Corp grew its stake in HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.